{"created":"2021-10-22T04:50:59.745271+00:00","id":2001668,"links":{},"metadata":{"_buckets":{"deposit":"e73177fa-f420-4248-ba28-b18cba286711"},"_deposit":{"created_by":52,"id":"2001668","owner":"52","owners":[52],"owners_ext":{"displayname":"kuro","username":"kuro"},"pid":{"revision_id":0,"type":"depid","value":"2001668"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:02001668","sets":["2780:1789","3:62:5592:7432"]},"author_link":["573"],"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"12","bibliographicPageEnd":"1201","bibliographicPageStart":"1197","bibliographicVolumeNumber":"46","bibliographic_titles":[{"bibliographic_title":"Journal of dermatology","bibliographic_titleLang":"en"}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wiley","subitem_publisher_language":"en"}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"31638282","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1111/1346-8138.15103","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2019 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.","subitem_rights_language":"en"}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0385-2407","subitem_source_identifier_type":"PISSN"}]},"item_5_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00696658","subitem_source_identifier_type":"NCID"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yokota, Kenji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Uchi, Hiroshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Uhara, Hisashi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yoshikawa, Shusuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takenouchi, Tatsuya","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Inozume, Takashi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ozawa, Kentaro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ihn, Hironobu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"藤澤, 康弘","creatorNameLang":"ja"},{"creatorName":"フジサワ, ヤスヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"FUJISAWA, Yasuhiro","creatorNameLang":"en"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Qureshi, Anila","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"de Pril,  Veerle","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Otsuka, Yasushi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Weber, Jeffrey","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamazaki, Naoya","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-10-22"}],"displaytype":"detail","filename":"JD_46-12-1197.pdf","filesize":[{"value":"180 KB"}],"format":"application/pdf","licensetype":"license_5","url":{"objectType":"fulltext","url":"https://tsukuba.repo.nii.ac.jp/record/2001668/files/JD_46-12-1197.pdf"},"version_id":"d328a712-0e70-4ffe-a0ba-4f1469f6ae34"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study","subitem_title_language":"en"}]},"item_type_id":"5","owner":"52","path":["1789","7432"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-10-22"},"publish_date":"2021-10-22","publish_status":"0","recid":"2001668","relation_version_is_last":true,"title":["Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study"],"weko_creator_id":"52","weko_shared_id":-1},"updated":"2022-04-27T09:50:27.006457+00:00"}